Republic Of Kazakhstan

There are number of advantages for clinical trials in Kazakhstan:

  • Full compliance with the international standards of ICH GCP (Good Clinical Practice).
  • Detailed documentation and a focus on accountability and quality indicators allow to obtain data of the highest accuracy.
  • A large population. Population on 1 January 2017 is 17 926 500 people.
  • Relatively low accessibility of high-tech methods of diagnosis and treatment for the population, which also improves typing speed and ensures inclusion in the study patients without prior treatment and with different degrees of severity of the process.
  • Legislation and the system of organization of clinical research in the Republic of Kazakhstan also make it extremely attractive for clinical research. Term of authorization for conducting clinical studies is up to 30 working days.
  • The registration`s duration is up to 210 calendar days from the date of acceptance of the application for state registration prior to the issuance of the registration certificate.
  • Cost of state registration of medicines (excluding the cost of conducting a clinical study) is much lower than in the US and Europe, about 3, 000 U.S. dollars.
  • High qualification of clinical researchers in the field of clinical trials allows to obtain data of excellent quality. More than 60% of clinical researchers are PhDs, about 40% teach at major universities.
  • Experience and education of physicians conducting clinical research, allow to obtain data of excellent quality, which is confirmed by inspections by regulatory authorities.
  • The potential to reduce the budget of the clinical trial.
  • In the middle of 2017 year, it is planned to release a single for all state members of The Eurasian economic community of the document on the procedure for the authorization of clinical trials that will make the procedure uniform for all States parties.